Benyakan PongkitwitoonSeiichi SakamotoRika NagamitsuWaraporn PutalunHiroyuki TanakaSatoshi MorimotoKhon Kaen UniversityMahidol UniversityKyushu University2019-08-232019-08-232018-02-28Planta Medica. Vol.84, No.14 (2018), 1038-104414390221003209432-s2.0-85042787997https://repository.li.mahidol.ac.th/handle/20.500.14594/45236© Georg Thieme Verlag KG Stuttgart . New York. Homoharringtonine (HHT), also known as omacetaxine, is a natural compound found in the genus Cephalotaxus and is a promising pharmaceutical drug used for the treatment of chronic or accelerated phase chronic myeloid leukemia. As a tool for the quantitative determination of HHT, a specific monoclonal antibody against HHT (MAb 6A1) was generated by conjugates prepared via sodium periodate-mediated oxidation. The developed indirect competitive enzyme-linked immunosorbent assay (icELISA) using MAb 6A1 was found to be highly specific and sensitive with a limit of detection for HHT of 48.8 ng/mL. Validation assays to evaluate precision and accuracy of the method were conducted by the use of intra- and inter-assay analysis, recovery test, and comparison analysis between the amounts of HHT determined by ELISA and high-performance liquid chromatography. These results revealed that the established icELISA using MAb 6A1 is specific, sensitive, and reliable enough to be applied to the qualitative analysis for HHT. Furthermore, the results of this study support the usefulness of sodium periodate as a reagent for the conjugation between Cephalotaxus alkaloids and proteins for producing specific antibodies.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyChemistryMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1055/a-0578-8689